A phase III study comparing single-agent olaparib or the combination of cediranib and olaparib to standard platinum-based chemotherapy in recurrent platinum-sensitive ovarian cancer
Abstract No : 6003
Abstract Type : Oral Abstract Session
Indication : Ovarian
Intervention : Olaparib + Cediranib
Company : U.S. National Institutes of Health
Technology : PARP inhibitor
Conclusion:
C+O demonstrated similar activity to SOC in relapsed plat-sensitive ovca but did not meet the primary endpoint of improved PFS
Commentary:
A rare failure of Olaparib brought a lot of disappointment for ovarian cancer patient community
